Immunovant's IMVT-1402 Enters Phase 2b for Graves' Disease Treatment
Immunovant Sciences is conducting Phase 2b trial of IMVT-1402 for adults with Graves' disease unresponsive to antithyroid drugs.
Asset / Drug
Drug and asset intelligence for IMVT-1402 with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.
No catalysts indexed for this entity yet.
No catalysts indexed for this entity yet.
Newsletter
Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.
No paywall. No spam. Unsubscribe anytime.